第二代抗雄激素联合雄激素剥夺治疗与放疗在高危前列腺癌根治性治疗中的应用
综述探讨高危局限性前列腺癌在根治性放疗背景下,ADT联合第二代抗雄激素的证据。ASCO与NCCN指南已更新推荐考虑联合。STAMPEDE等试验显示阿比特龙酯联合泼尼松可带来总生存获益,并提高无病生存和无转移生存概率。
要点
- ASCO与NCCN指南更新推荐:非去势局部晚期高危/极高危非转移或淋巴结阳性前列腺癌放疗时,可考虑ADT联合第二代抗雄激素。
- 阿比特龙酯联合泼尼松在高危/极高危局限、淋巴结阳性及寡转移激素敏感前列腺癌中显示总生存获益。
- 第二代抗雄激素可能通过抑制DNA修复增敏放疗并减轻ADT耐药,相关临床试验正在进行。
核心结论
- 近期数据显示,阿比特龙酯联合泼尼松在高危和极高危局限、淋巴结阳性及寡转移激素敏感前列腺癌中带来总生存获益,并提高无病生存和无转移生存概率,支持在知情决策后使用强效AR抑制剂。
研究设计与样本
- 本文为综合性综述,回顾已发表及会议摘要证据,重点纳入评估ADT联合第二代抗雄激素用于根治性放疗的II期和III期试验,尤其关注STAMPEDE试验中阿比特龙酯的结果。
主要发现
- 近期数据提示阿比特龙酯联合泼尼松在高危和极高危局限、淋巴结阳性及寡转移激素敏感前列腺癌中具有总生存获益,并提高无病生存和无转移生存概率。
- 综述讨论了第二代抗雄激素可能通过抑制DNA修复减轻ADT耐药并提供放疗增敏的生物学机制。
- 正在进行的强效AR抑制剂联合ADT用于非转移高危放疗场景的临床试验可能为未来治疗指南提供信息。
关键数值与推荐
- ASCO循证指南与NCCN指南更新推荐:对接受放疗的非去势局部晚期高危和极高危非转移或淋巴结阳性前列腺癌患者,考虑在ADT基础上加用第二代抗雄激素。
- STAMPEDE试验评估了阿比特龙酯联合泼尼松方案。
临床怎么用
- ASCO与NCCN指南推荐考虑在ADT基础上加用第二代抗雄激素,适用于接受放疗的非去势局部晚期高危和极高危非转移或淋巴结阳性前列腺癌患者。
- 作者认为,近期数据支持在知情决策后于上述场景使用强效AR抑制剂。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evolving data suggest that men with high-risk localized prostate cancer may benefit from more potent androgen receptor inhibition in the context of curative intent radiotherapy. Recently updated American Society for Clinical Oncology (ASCO) evidence-based guidelines and the National Comprehensive Cancer Network (NCCN) Guidelines have updated recommendations for the consideration of adding second generation anti-androgens to androgen deprivation therapy (ADT) in men receiving radiation therapy (RT) for noncastrate locally advanced high and very high risk nonmetastatic or node positive prostate cancer. METHODS AND RESULTS: We conducted a comprehensive review of existing published and abstract presented evidence behind RT with ADT for the definitive management of high-risk prostate cancer, particularly focused on the current phase II and III trial evidence for the addition of second generation anti-androgens to ADT in definitive RT treatment of high-risk prostate cancer and specifically focused on the recent STAMPEDE trial results with abiraterone acetate. We review the biological mechanisms in which second generation anti-androgens may help mitigate ADT resistance and provide radiosensitization through inhibition of DNA repair. Finally, we discuss ongoing clinical trials of potent androgen receptor (AR) inhibitors with ADT in this non-metastatic high-risk radiotherapy setting that may inform on future treatment guidelines. CONCLUSIONS: Recent data suggest an overall survival benefit as well as increased probabilities of disease free and metastasis free survival in men with high and very high-risk localized, node positive, and oligometastatic hormone sensitive prostate cancer with abiraterone acetate and prednisone and support the use of potent AR inhibitors in this setting after informed decision making.
引用
- Wang EC, Lee WR, Armstrong AJ, et al. Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 36203051. doi:10.1038/s41391-022-00598-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。